Elotuzumab (Empliciti®) Horizons Infosheet

This Horizons Infosheet contains information about elotuzumab, a drug being investigated for the treatment of myeloma.  

This Infosheet covers key questions about elotuzumab, including: 

  • What is elotuzumab? 
  • What is a monoclonal antibody? 
  • How does elotuzumab work? 
  • How is elotuzumab given? 
  • What evidence exists to support the use of elotuzumab? 
  • What are the possible known side effects of elotuzumab? 
  • Is elotuzumab currently available in any UK clinical trials? 
  • Availability of elotuzumab in the UK 
  • Future directions 

Key points you can read about in this Infosheet include:  

  • Elotuzumab is a drug being investigated for the treatment of myeloma 
  • Elotuzumab is a monoclonal antibody drug which targets the SLAMF7 protein found on the surface of myeloma cells 
  • Elotuzumab has been licensed for use in Europe and the UK in combination with other anti-myeloma drugs, for relapsed and refractory patients 
  • Elotuzumab is not yet widely available in the UK because it has not been approved for use in myeloma on the NHS. However, patients may be treated with it as part of a clinical trial 
  • Side effects seen so far include infusion reaction, infections and low white blood cell levels 

Myeloma UK Elotuzumab Horizons Infosheet

PDF / 381KB Download
Close-up photograph of a hand holding a mobile phone.

Stay in touch

We’d love to stay in touch. Join our mailing list to receive updates from Myeloma UK including our monthly newsletter and updates about our services, research, campaigns and other ways you can get involved.